DEFA14A: STAAR Surgical, Alcon Amend Merger Deal with Price Bump

STAAR Surgical Company and Alcon Inc. announced an amendment to their merger agreement, increasing the cash consideration for STAAR shares to $30.75 per share.

Summary

• STAAR Surgical Company and Alcon Inc. amended their merger agreement, increasing the aggregate cash consideration for each share of STAAR common stock to $30.75, an increase of $2.75 per share from the prior agreement.
• The revised $30.75 price represents approximately a 66% premium to STAAR's closing stock price on August 4, 2025, and approximately a 10% premium to the initial $28 per share offer.
• The offer remains 100% cash and is intended to address shareholder objections to the previous merger price and management compensation terms.
• The amendment modifies the approach to Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) for employees.
• The Special Meeting of Stockholders is still scheduled for Friday, December 19, 2025, with the record date remaining October 24, 2025.
• Upon closing, in-the-money stock options will automatically vest, and holders will receive a cash payment equal to the difference between $30.75 and the exercise price, less tax withholding.
• Out-of-the-money options (exercise price of $30.75 or more) will be cancelled without payment.
• STAAR RSUs will generally convert into Alcon RSUs of equivalent value, maintaining existing vesting terms, with a double-trigger vesting provision for awards granted before August 4, 2025, in case of involuntary termination post-merger.
• STAAR PSUs will generally convert into Alcon RSUs of equivalent value, with performance deemed achieved at 100% of target, and new vesting terms (50% post-closing, 50% one-year anniversary), also including a double-trigger vesting provision.

Sentiment

Score: 8

Explanation: The significant increase in the merger consideration, coupled with the resolution of shareholder objections and favorable adjustments to employee compensation, indicates a positive development for STAAR's shareholders and employees, making the transaction more likely to proceed successfully.

Positives

• The merger consideration increased by $2.75 per share to $30.75, representing a ~10% increase from the prior offer.
• The $30.75 per share offer represents a substantial ~66% premium to STAAR's closing stock price on August 4, 2025.
• The amendment addresses and aims to resolve prior shareholder objections regarding the merger price and management compensation.
• The offer remains 100% cash, providing certainty for shareholders.
• Unvested in-the-money stock options will automatically vest upon closing, allowing holders to receive cash payments.
• Performance conditions for PSUs are eliminated, with performance deemed achieved at 100% of target, simplifying vesting.
• RSUs and PSUs granted before August 4, 2025, benefit from a double-trigger vesting provision, accelerating vesting if employment is involuntarily terminated within 12 months post-closing.

Negatives

• The merger transaction was previously contested, and shareholders had expressed objections to the initial $28 per share merger price and other terms.
• Out-of-the-money options (with an exercise price of $30.75 or more) will be cancelled upon closing, with no payment made to holders.

Risks

• The occurrence of any event, change, or other circumstances that could lead to the termination of the merger agreement or cause the transaction to be delayed or fail to occur.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain certain required regulatory approvals or to satisfy any other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and other business partners.
• Inability to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

Management expects to continue operating business as usual until the merger closes. The company encourages employees to remain focused on their responsibilities to advance the business and impact customers and patients. The company undertakes no obligation to update or revise any forward-looking statements unless required by applicable law.

Management Comments

• "This is another clear sign that Alcon believes strongly in STAAR, its employees and our bright future."
• "I am proud of each of you, as you have done a great job of staying focused on the business despite the noise that has surrounded STAAR in the last several months."
• "There are no changes to our go forward approach as a result of this new amendment to the merger agreement. Prior to the closing of the merger, we will continue to operate business as usual."

Industry Context

The amendment to the merger agreement between STAAR Surgical, a company specializing in implantable lenses, and Alcon, a global leader in eye care, reflects ongoing consolidation within the ophthalmology and medical device sectors. The increased offer price and resolution of shareholder objections suggest Alcon's strong commitment to the acquisition, potentially driven by the strategic value of STAAR's technology and market position in a competitive and growing eye care market.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against the Company related to the proposed transaction is a potential risk.

Stakeholder Impact

• Shareholders: Will receive an increased cash consideration of $30.75 per share, representing a higher premium and addressing previous objections, which is a positive financial outcome.
• Employees: Benefit from automatic vesting of in-the-money stock options, conversion of RSUs to Alcon RSUs with maintained vesting terms, and conversion of PSUs to Alcon RSUs with performance deemed achieved at 100% target and modified vesting. Certain awards also gain double-trigger vesting protection.
• Management: Compensation terms related to RSUs and PSUs were modified to address shareholder concerns, potentially improving alignment and reducing friction.

Next Steps

• Stockholders are scheduled to vote on the proposed merger at the Special Meeting on December 19, 2025.
• STAAR Surgical Company will continue to operate business as usual until the closing of the merger.
• Promptly following the closing of the merger, shareholders will receive instructions on how to surrender their shares to STAAR's exchange agent for payment.

Key Dates

Recommendation

The increased offer price of $30.75 per share, representing a significant premium and addressing prior shareholder objections, makes the merger more attractive and likely to close. As the offer is 100% cash, there is limited upside beyond the offer price. Investors holding STAAR stock should hold to realize the increased cash consideration upon the expected completion of the merger, as the risk of the deal falling through has been mitigated by the improved terms.

Keywords

STAAR Surgical, Alcon, merger agreement, acquisition, stock premium, cash offer, shareholder objections, RSU, PSU, stock options, corporate governance, SEC filing, DEFA14A, ophthalmology, medical devices